ArticleInternational journal of antimicrobial agents2009
Targeted antimicrobial activity of a specific IgG-SMAP28 conjugate against Porphyromonas gingivalis in a mixed culture.
Article in International journal of antimicrobial agents, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Hybrid and conjugated antimicrobial peptides: new tactics to counter bacterial resistance.Frontiers in microbiology · 2026Review
- Antimicrobial Biomaterials Based on Physical and Physicochemical Action.Advanced healthcare materials · 2024Review
- Conjugated therapeutic proteins as a treatment for bacteria which trigger cancer development.iScience · 2024Review
- Interconnections Between the Oral and Gut Microbiomes: Reversal of Microbial Dysbiosis and the Balance Between Systemic Health and Disease.Microorganisms · 2021Review
- Antimicrobial Prosthetic Surfaces in the Oral Cavity-A Perspective on Creative Approaches.Microorganisms · 2020Review
- Towards Robust Delivery of Antimicrobial Peptides to Combat Bacterial Resistance.Molecules (Basel, Switzerland) · 2020Review
- Targeted antimicrobial therapy in the microbiome era.Molecular oral microbiology · 2017Review
- Repurposing AM404 for the treatment of oral infections by Porphyromonas gingivalis.Clinical and experimental dental research · 2017Article
- Design and Application of Antimicrobial Peptide Conjugates.International journal of molecular sciences · 2016Review
- Pro-moieties of antimicrobial peptide prodrugs.Molecules (Basel, Switzerland) · 2015Review
- Potential of host defense peptide prodrugs as neutrophil elastase-dependent anti-infective agents for cystic fibrosis.Antimicrobial agents and chemotherapy · 2014Article
- Targeted antimicrobial peptides.Frontiers in immunology · 2012Article
- Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals?International journal of antimicrobial agents · 2011Review
- Antibacterial Peptides: Opportunities for the Prevention and Treatment of Dental Caries.Probiotics and antimicrobial proteins · 2011Article
- Communication: Antimicrobial Activity of SMAP28 with a Targeting Domain for Porphyromonas gingivalis.Probiotics and antimicrobial proteins · 2010Article
- Review
- Mapping the landscape of antimicrobial peptides in periodontology: A scoping review.Journal of Indian Society of PeriodontologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Antimicrobial peptides coupled to a ligand, receptor or antibody for a specific pathogenic bacteria could be used to develop narrow-spectrum pharmaceuticals with 'targeted' antimicrobial activity void of adverse reactions often associated with the use of broad-spectrum antibiotics. To assess the feasibility of this approach, in this study sheep myeloid antimicrobial peptide (SMAP) 28 was linked to affinity- and protein G-purified rabbit immunoglobulin G (IgG) antibodies specific to the outer surface of Porphyromonas gingivalis strain 381. The selective activity of the P. gingivalis IgG-SMAP28 conjugate was then assessed by adding it to an artificially generated microbial community containing P. gingivalis, Aggregatibacter actinomycetemcomitans and Peptostreptococcus micros. The specificity of the P. gingivalis IgG-SMAP28 conjugate in this mixed culture was concentration-dependent. The conjugate at 50 microg protein/mL lacked specificity and killed P. gingivalis, A. actinomycetemcomitans and P. micros. The conjugate at 20 microg protein/mL was more specific and killed P. gingivalis. This is an initial step to develop a selective antimicrobial agent that can eliminate a specific periodontal pathogen, such as P. gingivalis, from patients with periodontal disease without harming the normal commensal flora.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.